Zenith Drugs Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%
- Company has a healthy return on capital (ROCE) of 23.7%
- Company maintains a comfortable, low leverage position
CONS
- Operating cash flow has been negative in recent years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.72x)
- Working capital days have increased from 35 to 119 days
- Though reporting repeated profits, the company pays out little dividend (8.9%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ZENITHDRUG | 42.75 | 7.64 | 73.31 | 0.00 | — | — | — | — | 12.96 | — |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
No quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 115 | 132 | |
| 85 | 105 | 115 | |
| Operating Profit | 7 | 9 | 16 |
| OPM % | 7.59% | 8.04% | 12.53% |
| 1 | 1 | 1 | |
| Interest | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before Tax | 4 | 7 | 13 |
| Tax % | 28.99% | 26.68% | 28.24% |
| Net Profit | 3 | 5 | 10 |
| EPS | 78.22 | 122.03 | 5.59 |
| Dividend Payout % | 0.00% | 0.00% | 8.94% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -40%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 28%
- Last Year:
- 24%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0 | 0 | 17 |
| 12 | 17 | 45 | |
| 19 | 26 | 23 | |
| Trade Payables | 35 | 51 | 43 |
| 3 | 3 | 7 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| Capital Work in Progress | 3 | 0 | 4 |
| 12 | 24 | 26 | |
| 0 | 0 | 67 | |
| Cash & Bank | 3 | 0 | 9 |
| 40 | 62 | 18 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 6 | -3 | -13 | |
| Cash from Investing | -5 | -0 | 26 |
| Cash from Financing | 1 | 5 | -4 |
| 1 | -0 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| PER SHARE | |||
| EPS (₹) | 78.45 | 122.02 | 5.59 |
| Book Value (₹) | 302.27 | 443.04 | 36.31 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.50 |
| Cash EPS (₹) | 3.71 | 5.15 | 6.39 |
| PROFITABILITY | |||
| Operating Margin % | 8.70% | 8.15% | 10.97% |
| Net Margin % | 3.41% | 3.81% | 6.42% |
| ROE % | 25.88% | 32.74% | 24.12% |
| ROCE % | 21.51% | 24.47% | 25.15% |
| 4.56% | 5.86% | 8.28% | |
| EFFICIENCY | |||
| Debtor Days | 128 | 116 | 142 |
| Inventory Days | 48 | 51 | 60 |
| Payable Days | 317 | 277 | 301 |
| -141 | -110 | -99 | |
| FINANCIAL HEALTH | |||
| Debt to Equity (x) | 1.56x | 1.47x | 0.40x |
| Interest Coverage (x) | 2.97x | 3.68x | 5.48x |
| 1.15x | 1.17x | 1.77x | |
| GROWTH | |||
| Revenue Growth % | 0.00% | 24.95% | 14.93% |
| Operating Profit Growth % | 0.00% | 31.07% | 82.21% |
| Net Profit Growth % | 0.00% | 55.99% | 97.66% |
| 0.00% | 0.00% | -95.42% | |
| VALUATION | |||
| P/E (x) | 0.00x | 0.00x | 11.21x |
| P/B (x) | 0.00x | 0.00x | 1.73x |
| Dividend Yield % | 0.00% | 0.00% | 0.80% |
| 0.00x | 0.00x | 6.48x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for ZENITHDRUG
Loading news…
AI Stock Analyst
Zenith Drugs Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account